Blog | Think Bold, Think Scientific, Think Veristat

Gain the latest insights and trends in clinical trials, patient recruitment, data analysis, adaptive design, regulatory submissions and approvals.

Sign Up Today

3 min read

Regulatory Guidance Monthly Review - Aug 2021

August 2021 

Each month, Veristat's regulatory team tracks and shares a selection of new Regulatory Guidance updates from the US Food & Drug Administration (FDA)  that are pertinent to the governance of clinical trials and drug, biologic, or medical...

READ MORE

2 min read

Part Two: Key Takeaways for Successful Development of Cell and Gene Therapies

As mentioned in part one of this blog, while the development of cell and gene therapy (C&GT) products has accelerated in recent years, even the best therapeutic may not reach patients who need it if study design and execution are not done correctly. It...

READ MORE

3 min read

Regulatory Guidance Monthly Review - July 2021

July 2021 

Each month, Veristat's regulatory team tracks and shares a selection of new Regulatory Guidance updates from the US Food & Drug Administration (FDA)  that are pertinent to the governance of clinical trials and drug, biologic, or medical...

READ MORE

2 min read

Part One: Key Takeaways for Successful Development of Cell and Gene Therapies

Cell and gene therapy (C&GT) products are beginning to deliver on their long-hoped-for promise. CAR-T technology has proven to be a powerful new weapon in cancer treatment, and FDA approval of Luxturna in 2017 demonstrated the potential of gene therapies...

READ MORE

3 min read

Regulatory Guidance Monthly Review - June 2021

June 2021 

Each month, Veristat's regulatory team tracks and shares a selection of new Regulatory Guidance updates from the US Food & Drug Administration (FDA)  that are pertinent to the governance of clinical trials and drug, biologic, or medical...

READ MORE

4 min read

Planning the Way Forward in Neurodegenerative Disease Studies

Clinical trials involving gene therapies for the treatment of Central Nervous System (CNS) indications are some of the more complex in the field of gene and cell therapy (G&CT) development.  During the lockdown, the Food and Drug Administration (FDA)...

READ MORE

2 min read

Regulatory Guidance Monthly Review - May 2021

May 2021 

Each month, Veristat's regulatory team tracks and shares a selection of new Regulatory Guidance updates from the US Food & Drug Administration (FDA)  that are pertinent to the governance of clinical trials and drug, biologic, or medical...

READ MORE

3 min read

Mental Health: Connecting Openly & Honestly

As we say goodbye to Mental Health Month in May and welcome Men’s Mental Health Month in June, there is no better time to check in with ourselves and each other.

READ MORE

1 min read

Veristat Raises >$350K For Rare Cancer Research

Team Veristat Participate in Cycle for Survival 2021 - Virtually

 

For the past seven years, Veristat has participated in Memorial Sloan Kettering's Cycle for Survival, the movement to beat rare cancers. Founded in partnership with Equinox fitness club...

READ MORE

2 min read

Regulatory Guidance Monthly Review - April 2021

April 2021 

Each month, Veristat's regulatory team tracks and shares a selection of new Regulatory Guidance updates from the US Food & Drug Administration (FDA)  that are pertinent to the governance of clinical trials and drug, biologic, or medical...

READ MORE